Pascal Hänggi1, Butrint Aliu2, Kea Martin2, Ruben Herrendorff2, Andreas Johann Steck2. 1. From the Polyneuron Pharmaceuticals AG (P.H.,K.M.,R.H.), Basel; Molecular Pharmacy (P.H.,B.A.,R.H.), Pharmacenter, University of Basel; and Clinic of Neurology (A.J.S.), Department of Medicine, University Hospital Basel, University of Basel, Switzerland. pascalrhaenggi@gmail.com. 2. From the Polyneuron Pharmaceuticals AG (P.H.,K.M.,R.H.), Basel; Molecular Pharmacy (P.H.,B.A.,R.H.), Pharmacenter, University of Basel; and Clinic of Neurology (A.J.S.), Department of Medicine, University Hospital Basel, University of Basel, Switzerland.
Abstract
BACKGROUND AND OBJECTIVES: The objective of the retrospective analysis was to test the hypothesis that changes in serum anti-myelin-associated glycoprotein (MAG) autoantibodies are associated with clinical response to immunotherapy in patients with anti-MAG neuropathy. METHODS: As of January 29, 2020, we used anti-myelin-associated glycoprotein-related search strings in the Medline database to identify studies that provided information on anti-MAG immunoglobulin M (IgM) autoantibodies and clinical outcomes during immunotherapies. The relative change in anti-MAG IgM titers, paraprotein levels, or total IgM was determined before, during, or posttreatment, and the patients were assigned to "responder," "nonresponder,"' or "acute deteriorating" category depending on their clinical response to treatment. The studies were qualified as "supportive" or "not supportive" depending on the percentage of patients exhibiting an association between relative change of anti-MAG antibody titers or levels and change in clinical outcomes. RESULTS: Fifty studies with 410 patients with anti-MAG neuropathy were included in the analysis. Forty studies with 303 patients supported the hypothesis that a "responder" patient had a relative reduction of anti-MAG antibody titers or levels that is associated with clinical improvements and "nonresponder" patients exhibited no significant change in anti-MAG IgM antibodies. Six studies with 93 patients partly supported, and 4 studies with 26 patients did not support the hypothesis. DISCUSSION: The retrospective analysis confirmed the hypothesis that a relative reduction in serum anti-MAG IgM antibodies is associated with a clinical response to immunotherapies; a sustained reduction of at least 50% compared with pretreatment titers or levels could be a valuable indicator for therapeutic response.
BACKGROUND AND OBJECTIVES: The objective of the retrospective analysis was to test the hypothesis that changes in serum anti-myelin-associated glycoprotein (MAG) autoantibodies are associated with clinical response to immunotherapy in patients with anti-MAG neuropathy. METHODS: As of January 29, 2020, we used anti-myelin-associated glycoprotein-related search strings in the Medline database to identify studies that provided information on anti-MAG immunoglobulin M (IgM) autoantibodies and clinical outcomes during immunotherapies. The relative change in anti-MAG IgM titers, paraprotein levels, or total IgM was determined before, during, or posttreatment, and the patients were assigned to "responder," "nonresponder,"' or "acute deteriorating" category depending on their clinical response to treatment. The studies were qualified as "supportive" or "not supportive" depending on the percentage of patients exhibiting an association between relative change of anti-MAG antibody titers or levels and change in clinical outcomes. RESULTS: Fifty studies with 410 patients with anti-MAG neuropathy were included in the analysis. Forty studies with 303 patients supported the hypothesis that a "responder" patient had a relative reduction of anti-MAG antibody titers or levels that is associated with clinical improvements and "nonresponder" patients exhibited no significant change in anti-MAG IgM antibodies. Six studies with 93 patients partly supported, and 4 studies with 26 patients did not support the hypothesis. DISCUSSION: The retrospective analysis confirmed the hypothesis that a relative reduction in serum anti-MAG IgM antibodies is associated with a clinical response to immunotherapies; a sustained reduction of at least 50% compared with pretreatment titers or levels could be a valuable indicator for therapeutic response.
Authors: Giancarlo Comi; Luisa Roveri; Antony Swan; Hugh Willison; Martin Bojar; Isabel Illa; Clementine Karageorgiou; Eduardo Nobile-Orazio; Peter van den Bergh; Tony Swan; Richard Hughes; Jaques Aubry; Nicole Baumann; Robert Hadden; Michael Lunn; Martin Knapp; Jean-Marc Léger; Pierre Bouche; Radim Mazanec; Nicoletta Meucci; Frans van der Meché; Klaus Toyka Journal: J Neurol Date: 2002-10 Impact factor: 4.849
Authors: A Pestronk; J Florence; T Miller; R Choksi; M T Al-Lozi; T D Levine Journal: J Neurol Neurosurg Psychiatry Date: 2003-04 Impact factor: 10.154
Authors: S Kelm; A Pelz; R Schauer; M T Filbin; S Tang; M E de Bellard; R L Schnaar; J A Mahoney; A Hartnell; P Bradfield Journal: Curr Biol Date: 1994-11-01 Impact factor: 10.834
Authors: Marinos C Dalakas; Goran Rakocevic; Mohammad Salajegheh; James M Dambrosia; Angelika F Hahn; Raghavan Raju; Beverly McElroy Journal: Ann Neurol Date: 2009-03 Impact factor: 10.422
Authors: J M F Niermeijer; M Eurelings; M W van der Linden; H M Lokhorst; H Franssen; K Fischer; L L Teunissen; L H van den Berg; F Schobben; J H J Wokke; N C Notermans Journal: Neurology Date: 2007-07-03 Impact factor: 9.910
Authors: Jahanzaib Khwaja; Shirley D'Sa; Monique C Minnema; Marie José Kersten; Ashutosh Wechalekar; Josephine M Vos Journal: Haematologica Date: 2022-09-01 Impact factor: 11.047